2005
DOI: 10.1007/s00280-005-0090-8 View full text |Buy / Rent full text
|
|

Abstract: Our results suggest that lymphomas overexpress LDL receptors that make room for using LDE as drug-targeting vehicle and that the LDE-etoposide preparation is suitable for patient use.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
2
1
1
35
0
13

Year Published

2011
2011
2016
2016

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

1
35
0
13
Order By: Relevance
“…In the etoposide, 300 mg/m 2 dose/3 weeks, administered over 6 cycles. 17 This dose scheme corresponds to those routinely used in the clinical oncology practice. During the treatment, no clinical and laboratorial toxicities, including anemia or other myelotoxicities, were observed in both patients.…”
Section: Discussionmentioning
See 1 more Smart Citation
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 14 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…In the etoposide, 300 mg/m 2 dose/3 weeks, administered over 6 cycles. 17 This dose scheme corresponds to those routinely used in the clinical oncology practice. During the treatment, no clinical and laboratorial toxicities, including anemia or other myelotoxicities, were observed in both patients.…”
Section: Discussionmentioning
“…15 Reduction of toxicity of chemotherapeutic agents by associating them to LDE was confirmed at clinical level. In trials enrolling patients with advanced cancers treated with LDE-carmustine, 10 LDE-paclitaxel, 16 and LDE-etoposide, 17 the toxicity of high-dose treatments was minimal or absent.…”
mentioning
“…In those leukemias and also in Hodgkin and non-Hodgkin lymphomas, LDL cholesterol levels may decrease, resulting from the increased removal of LDL from the circulation by the neoplastic tissues. [3][4][5][6] correspondence: raul c Maranhão laboratório de Metabolismo de lípides, instituto do coração (incOr) do hospital das clínicas FMUsP, 44 avenida Doutor enéas de carvalho aguiarBloco 2, 1ss, são Paulo 05403-900, Brazil Tel +55 11 2661 5951 Fax +55 11 2661 5574 email ramarans@usp.br…”
Section: Introductionmentioning
“…Because it is prepared only with lipids present in the organism, LDE has no immunogenic potential and no safety issues related to materials in the nanoemulsion composition. 5,14,22,23 Due to the aggressiveness of the malignant neoplastic processes, adjuvant strategies with the potential to increase the effectiveness of anticancer therapies should always be considered for testing. In this respect, statins, the most important cholesterol-lowering class of drugs, have been reported as inducers of apoptosis and antitumor activity of antineoplastic drugs, such as carmustine, cisplatin, 5-fluorouracil, doxorubicin, and PTX, and investigated as adjuvants in cancer treatment and prevention.…”
Section: Introductionmentioning
See 1 more Smart Citation